Regorafenib offers survival benefit for patients with pre-treated gastric cancer Presented ByProf. Nick Pavlakis, University of Sydney, Australia TrialPhase 3, INTEGRATE IIa ConferenceASCO GI 2023 17 March, 2023 08:24
Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC ExpertDr Philippe Merle, Groupement Hospitalier Lyon Nord, France TrialREFINE ConferenceASCO 2020 17 September, 2020 14:45
